{"type":"trials","record":{"id":21789,"source_id":"clinicaltrials-gov","external_id":"NCT06425042","title":"Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity","brief_summary":"The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Finis Terrae University","enrollment":28,"countries":["Chile"],"start_date":"2024-03-01","completion_date":"2026-03-01","last_update_date":"2025-07-11","source_url":"https://clinicaltrials.gov/study/NCT06425042","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:10.338673+00:00","last_seen_at":"2026-09-25T06:05:47.306+00:00","metadata":{"sex":"ALL","acronym":"RESTORENAD","age_range":"60 Years to 80 Years","comparator":"PLA+EXTR","organization":"Finis Terrae University","interventions":["Nicotinamide Riboside (NR)","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Skeletal muscle mitochondrial respiratory capacity — 12 weeks","Quantification of proteins that regulate oxidative metabolism — 12 weeks","Skeletal muscle mitochondrial content — 12 weeks","Maximal aerobic capacity — 12 weeks","Walking speed and distance — 12 weeks","Seating and standing transitions — 12 weeks","Exercise efficiency — 12 weeks","Intrahepatic liver fat content — 12 weeks","Body weight — 12 weeks","Total muscle mass — 12 weeks","Total fat mass — 12 weeks","Fat-free mass — 12 weeks","NAD+ levels — 12 weeks","24h Blood pressure — 12 weeks","Resting energy expenditure — 12 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Healthy Aging","Lifestyle-related Condition","Metabolic Diseases","Nicotinamide Riboside (NR)","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: nicotinamide riboside.","quality_checked_at":"2026-09-25T06:05:48.394941+00:00","duplicate_cluster_key":"id:nct06425042","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-03-01 to 2026-03-01","comparator":"PLA+EXTR","confidence":"structured-source","population":"ALL · 60 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:05:47.312Z","intervention":["Nicotinamide Riboside (NR)","Placebo"],"participants":28,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Skeletal muscle mitochondrial respiratory capacity — 12 weeks","Quantification of proteins that regulate oxidative metabolism — 12 weeks","Skeletal muscle mitochondrial content — 12 weeks","Maximal aerobic capacity — 12 weeks","Walking speed and distance — 12 weeks","Seating and standing transitions — 12 weeks","Exercise efficiency — 12 weeks","Intrahepatic liver fat content — 12 weeks","Body weight — 12 weeks","Total muscle mass — 12 weeks","Total fat mass — 12 weeks","Fat-free mass — 12 weeks","NAD+ levels — 12 weeks","24h Blood pressure — 12 weeks","Resting energy expenditure — 12 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"nad-metabolism","is_published":true,"match_reasons":["Title contains controlled term: nicotinamide riboside.","Abstract contains controlled term: nad+, nicotinamide riboside.","Source terminology contains: nicotinamide riboside.","Title supplies longevity context: longevity.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"NAD metabolism","slug":"nad-metabolism"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/21789","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}